Your browser doesn't support javascript.
loading
Combined Let-7a and H19 Signature: A Prognostic Index of Progression-Free Survival in Primary Breast Cancer Patients / 한국유방암학회지
Journal of Breast Cancer ; : 142-149, 2018.
Article Dans Anglais | WPRIM | ID: wpr-714867
ABSTRACT

PURPOSE:

The long non-coding RNA H19, a conservatively imprinted gene, acts as a molecular sponge for the let-7 family, which has been identified as a set of tumor suppressors. However, the combined prognostic value of H19 and let-7a signature in breast cancer patients remains unclear.

METHODS:

In this research we assessed the prognostic value of the combined H19 and let-7a signature in breast cancer patients by retrospectively reviewing that data of 79 patients who underwent neoadjuvant chemotherapy; we also investigated the expression and function of H19 in breast cancer cell lines in vitro. Survival data were calculated using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate survival analyses were conducted using the Cox proportional hazards regression method. As determined using X-tile, the optimal cutoff value for the risk score to assess progression-free survival (PFS) based on the combined signature was –0.1.

RESULTS:

Patients with an overall positive treatment response had higher let-7a and lower H19 levels. In addition, let-7a expression was negatively correlated with H19 expression. Patients with a risk score of >–0.1 had shorter overall survival and PFS. In vitro data showed that chemoresistant cell lines exhibit higher H19 and lower let-7a levels and knockdown H19 restores paclitaxel sensitivity.

CONCLUSION:

Our results suggest that the combined let-7a and H19 signature is a novel prognostic factor for breast cancer patients treated with neoadjuvant chemotherapy.
Sujets)

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Porifera / Pronostic / Techniques in vitro / Région mammaire / Tumeurs du sein / Lignée cellulaire / Études rétrospectives / Paclitaxel / Survie sans rechute / Traitement néoadjuvant Type d'étude: Étude observationnelle / Étude pronostique Limites du sujet: Humains langue: Anglais Texte intégral: Journal of Breast Cancer Année: 2018 Type: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS

Texte intégral: Disponible Indice: WPRIM (Pacifique occidental) Sujet Principal: Porifera / Pronostic / Techniques in vitro / Région mammaire / Tumeurs du sein / Lignée cellulaire / Études rétrospectives / Paclitaxel / Survie sans rechute / Traitement néoadjuvant Type d'étude: Étude observationnelle / Étude pronostique Limites du sujet: Humains langue: Anglais Texte intégral: Journal of Breast Cancer Année: 2018 Type: Article